Enliven Therapeutics, Inc.
Total Trades
203
Buys
1
Sells
139
Largest Trade
$1M+
Insiders
9
Institutional Funds
94
Inst. Value
$1M+
Activist Filings
38
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 5K | $29.04 | Feb 10, 2026 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $500K+ | 20K | $26.75 | Jan 22, 2026 |
| Heyman Richard A. | Director | SELL | $15K–$50K | 1K | $26.75 | Jan 22, 2026 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $1M+ | 48K | $27.99 | Jan 13, 2026 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $1M+ | 133K | $26.23 | Jan 12, 2026 |
| Heyman Richard A. | Director | SELL | $100K–$500K | 14K | $25.02 | Jan 12, 2026 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $50K–$100K | 5K | $16.84 | Dec 23, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $21.02 | Dec 10, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 13K | $22.33 | Nov 21, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 13K | $21.82 | Nov 19, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $17.40 | Nov 12, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 13K | $22.08 | Oct 22, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 13K | $21.33 | Oct 21, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $20.40 | Oct 1, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Oct 1, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $50K–$100K | 4K | $20.25 | Sep 30, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $50K–$100K | 4K | $20.06 | Sep 30, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $15K–$50K | 2K | $20.03 | Sep 25, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $50K–$100K | 3K | $20.03 | Sep 25, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 7K | $19.39 | Sep 23, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 6K | $19.29 | Sep 19, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $20.24 | Sep 11, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $20.63 | Aug 29, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Aug 29, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Jul 30, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $20.46 | Jul 30, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 13K | $22.29 | Jul 23, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 13K | $22.52 | Jul 21, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $15K–$50K | 1K | $22.66 | Jul 14, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 1K | $2.48 | Jul 14, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $19.79 | Jul 9, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Jul 1, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $20.91 | Jul 1, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 13K | $21.40 | Jun 24, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 13K | $22.18 | Jun 18, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $22.55 | Jun 17, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Jun 17, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $20.34 | Jun 11, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 8K | $20.03 | Jun 5, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 8K | $20.05 | Jun 5, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $16.18 | May 29, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | May 29, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $50K–$100K | 5K | $16.31 | May 21, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $50K–$100K | 5K | $16.49 | May 21, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $18.39 | May 9, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 8K | $20.05 | May 5, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 8K | $20.06 | May 5, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Apr 30, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $18.69 | Apr 30, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $50K–$100K | 5K | $16.07 | Apr 23, 2025 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 94 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| ORBIMED ADVISORS LLC | 8.0M | $1M+ | SH |
| Fairmount Funds Management LLC | 3.7M | $1M+ | SH |
| VR Adviser, LLC | 3.2M | $1M+ | SH |
| Point72 Asset Management, L.P. | 1.5M | $1M+ | SH |
| Novo Holdings A/S | 1.5M | $1M+ | SH |
| Capital Research Global Investors | 1.3M | $1M+ | SH |
| Pictet Asset Management Holding SA | 1.3M | $1M+ | SH |
| STATE STREET CORP | 1.1M | $1M+ | SH |
| Soleus Capital Management, L.P. | 1.0M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 911K | $1M+ | SH |
| 5AM Venture Management, LLC | 772K | $1M+ | SH |
| Candriam S.C.A. | 453K | $1M+ | SH |
| Spruce Street Capital LP | 446K | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 357K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 355K | $1M+ | SH |
| Logos Global Management LP | 340K | $1M+ | SH |
| Patient Square Capital LP | 308K | $1M+ | SH |
| VANGUARD GROUP INC | 304K | $1M+ | SH |
| SPHERA FUNDS MANAGEMENT LTD. | 227K | $1M+ | SH |
| Exome Asset Management LLC | 222K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2025
5.4%
3.2M shares
SC 13G/A · Nov 5, 2025
13.3%
7.9M shares
SC 13G/A · Aug 14, 2025
9.9%
6.0M shares
Fairmount Funds Management LLC
SC 13G/A · Aug 14, 2025
6.3%
3.7M shares
SC 13G · Aug 14, 2025
5.2%
2.5M shares
SC 13G/A · Jul 17, 2025
5.1%
2.9M shares
SC 13D/A · Jun 17, 2025
13.4%
7.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2025
6.6%
3.2M shares
SC 13G/A · Feb 14, 2025
4.9%
2.4M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2024
8.5%
4.0M shares
SC 13G/A · Nov 14, 2024
2.2%
1.1M shares
SC 13G/A · Nov 14, 2024
3.7%
6 shares
Fairmount Funds Management LLC
SC 13G/A · Nov 14, 2024
6.8%
3.2M shares
SC 13G/A · Nov 14, 2024
8.7%
4.1M shares
SC 13G · Nov 13, 2024
5.7%
2.7M shares
SC 13G · Nov 8, 2024
6.2%
2.9M shares
SC 13G · Oct 24, 2024
6.2%
2.9M shares
SC 13D/A · Jul 29, 2024
4.1%
1.9M shares
SC 13D/A · May 20, 2024
16.8%
7.9M shares
SC 13D/A · Apr 15, 2024
5.1%
2.4M shares
SC 13D/A · Apr 4, 2024
19.2%
9.0M shares
SC 13D/A · Feb 16, 2024
7.8%
3.2M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Feb 15, 2024
7.2%
3.0M shares
SC 13G/A · Feb 14, 2024
0.1%
6 shares
SC 13G/A · Feb 14, 2024
5.7%
6 shares
SC 13G/A · Feb 14, 2024
7.0%
2.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2024
5.2%
2.1M shares
SC 13G/A · Feb 14, 2024
0.9%
389K shares
SC 13D/A · Feb 2, 2024
9.4%
3.9M shares
SC 13D/A · Aug 28, 2023
10.9%
4.5M shares
SC 13G · May 10, 2023
10.7%
4.4M shares
Fairmount Funds Management LLC
SC 13G · Apr 27, 2023
5.2%
2.1M shares
SC 13G · Apr 24, 2023
5.1%
2.1M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G · Mar 13, 2023
5.4%
2.2M shares
SC 13G · Mar 6, 2023
5.6%
6 shares
SC 13D · Mar 6, 2023
11.8%
4.8M shares
SC 13G/A · Feb 28, 2023
3.5%
1.4M shares
SC 13D · Feb 28, 2023
21.8%
8.9M shares